Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.

Description

Omda Cytodose, an oncology medication management solution from Omda, employs clinically validated protocols along with patient-specific parameters to ensure safer and more effective treatments for individuals battling cancer. This innovative system enhances the quality of care provided to oncology patients by fostering a seamless and collaborative treatment process among healthcare professionals, including doctors, pharmacists, and nurses. Omda Cytodose is designed to support a comprehensive range of adult and pediatric cancers, accommodating various medical treatments such as chemotherapy, immunotherapy, hormone therapy, and additional supportive medications. Initially created by a team of clinicians at one of Norway's premier cancer centers and introduced in 2001, Omda Cytodose has gained widespread adoption across healthcare regions in the Nordic countries, leading to the fulfillment of millions of medication orders. With a robust 15-year history marked by stability, reliability, and safety, the system is meticulously configured with chemotherapy protocols that reflect both national and international guidelines. This ensures that patients receive the most up-to-date treatment options available, further enhancing their chances of successful outcomes.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Lunit

Country

United States

Website

www.lunit.io/en

Vendor Details

Company Name

Omda

Founded

1999

Country

Norway

Website

omda.com/solutions/medication-management/omda-cytodose/

Product Features

Product Features

Alternatives

Alternatives

Oncora Reviews

Oncora

Oncora Medical
The Galen Platform Reviews

The Galen Platform

Ibex Medical Analytics